ScreenerHero
TMDXTransMedics Group, Inc.
NAS · US · Healthcare · Medical Devices · transmedics.com
92.16USD-1.92%Mkt Cap: 3.25B $P/E: 24.34

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides…

Industry Peers

Medical Devices
Screen all
ABT
Abbott Laboratories
$198.81BUSDP/E 36.9
SYK
STRYKER CORP. R
$120.66BUSDP/E 34.7
SYK
Stryker Corporation
$125.70BUSDP/E 33.9
2M6
Medtronic plc
$111.66BUSDP/E 24.9
BSX
Boston Scientific Corporation
$75.37BUSDP/E 21.1
EW
Edwards Lifesciences Corporation
$53.13BUSDP/E 54.9
SHL
Siemens Healthineers AG
$48.43BUSDP/E 19.9
GEHC
GE HealthCare Technologies Inc. Common Stock
$33.94BUSDP/E 17.2
DXCM
DexCom, Inc.
$33.92BUSDP/E 35.5
PHIA
Koninklijke Philips N.V.
$25.08BUSDP/E 20.7
ZBH
Zimmer Biomet Holdings, Inc.
$19.21BUSDP/E 24.5
SOON
Sonova Holding AG
$16.48BUSDP/E 26.9
PEN
Penumbra, Inc.
$12.87BUSDP/E 80.5
GMED
Globus Medical, Inc.
$11.86BUSDP/E 22.6
GKOS
Glaukos Corp
$11.18BUSD
EUZ
Eckert & Ziegler SE
$10.01BUSDP/E 17.1
PODD
Insulet Corporation
$10.51BUSDP/E 28.4
SN
Smith & Nephew plc
$9.73BUSDP/E 19.8
BIO
Bio-Rad Laboratories, Inc. Class A
$9.75BUSDP/E 44.3
DEMANT
Demant A/S
$8.82BUSDP/E 25.0

Key Statistics

Company
Market Cap3.25B $
Enterprise Value3.55B $
Revenue (TTM)668.47M $
Gross Profit362.81M $
Net Income (TTM)190.29M $
Revenue/Share19.47 USD
Last Price92.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees898
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)24.34
P/E (Forward)39.41
PEG1.24
EV/EBITDA30.66
EV/Revenue5.30
P/S4.71
P/B6.07
EPS (TTM)3.73
EPS (Forward)2.31
52W Range
60.1033% of range156.00
52W High156.00 USD
52W Low60.10 USD
Profitability
Gross Margin59.92%
Oper. Margin12.50%
EBITDA Margin17.30%
Profit Margin31.43%
ROE40.22%
ROA17.81%
Growth
Revenue Growth20.70%
Earnings Growth-55.80%
Cash Flow & Leverage
Operating CF192.84M $
CapEx (TTM)59.25M $
FCF Margin6.66%
FCF Yield1.37%
Net Debt395.04M $
Net Debt/EBITDA3.42
Balance Sheet
Debt/Equity1.10
Current Ratio6.63
Quick Ratio5.87
Book Value/Sh14.96 USD
Cash/Share13.63 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)97.30 USD
Upside (mean)+5.6%
Target Range65.00 USD – 125.00 USD
$65.00+5.6% to mean$125.00
# Analysts10
Ownership
Shares Out.34.56M
Float33.54M
Insiders3.64%
Institutions103.26%
Short Interest
Short Ratio9.1d
Short % Float34.45%
Short % Out.22.13%
Shares Short7.67M
Short (prev mo.)7.87M
Technical
SMA 5077.07 (+19.6%)
SMA 200106.46 (-13.4%)
Beta1.88
S&P 52W Chg18.16%
Avg Vol (30d)885.81K
Avg Vol (10d)743.00K
Technical Indicators
RSI (14)70.6
MACD4.4197
MACD Signal3.2801
MACD Hist.+1.1396
BB Upper95.23 USD
BB Middle81.20 USD
BB Lower67.18 USD
BB Width34.54%
ATR (14)4.324 USD
Vol Ratio (20d)0.72x